Emmaus Life Sciences earnings release, August 14, 2026

Emmaus Life Sciences, Inc. (EMMA) · Form 8-K, Item 2.02 · Filed · SEC filing

Emmaus Life Sciences Reports Quarterly Financial

Results

Torrance CA, August 14, 2026 - Emmaus Life Sciences,

Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026.

Highlights

“Under our previously announced License and

Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the

U.S. and its territories and possessions and Canada in exchange for an upfront cash payment and royalties on NIT’s sales of the licensed products. We recognized a part of the upfront payment and royalties as revenue which resulted in a 124% increase in net revenues for three month ended June 30, 2026 as compared to the same period in 2025,” commented Willis Lee, Chairman and Chief Executive

Officer of Emmaus. “We were also able to further reduce our operating expenses,” he added.

Financial and Operating Results

Net Revenues.

Net revenues for the three months ended June 30, 2026 were $6.3 million, compared to $2.8 million in the same period in 2025 due primarily to the recognition of revenue from the NIT license arrangement, partially offset by a decrease in direct Endari® sales.

Operating Expenses. Total operating expenses for the three months were $2.1 million compared to $3.0 million in the comparable period in 2025. The decrease was due primarily to decreased expenses attributable to the transfer of our sales force to NIT in connection with the license arrangement.

Income (Loss) From Operations.

Income from operations for the three months was $3.8 million compared to $0.4 million loss from operations in the same period in 2025. This was due to the increase in net revenues and lower operating expenses.

Other Expense.

The company realized other expense of $2.5 million for the three months compared to $1.4 million in the same period in 2025. The increase was primarily due to decreases of gain on lease modification and change in fair value of investment in equity securities.

Net Income (Loss). For the three months, the company realized a net income of $1.3 million, or $0.02 basic earnings per share based on approximately 70.2 million weighted-average common shares, compared to net loss of $1.1 million, or ($0.02) basic earnings per share based on approximately 63.9 million weighted-average common shares in the comparable period in 2025. The increase in net income was attributable primarily to the increase in net revenues.

Liquidity and Capital Resources. At June 30, 2026, the company had cash and cash equivalents of $2.8 million, compared to $2.1 million at December 31, 2025.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States,

Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus’ application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.

About Endari®

(prescription grade

L-glutamine oral powder)

Endari®, Emmaus’ prescription grade

L-glutamine oral powder, was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.

Indication

Endari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Important Safety Information

The most common adverse reactions (incidence

>10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari® in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing

Information of Endari® at: www.ENDARIrx.com/PI.²

About Sickle Cell Disease

There are approximately

100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.¹

The genetic mutation responsible for SCD causes an individual’s red blood cells to distort into a “C” or a sickle shape, reducing their ability to transport oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together, which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads to physical symptoms of incapacitating pain, tissue and organ damage, and early death.²

Financial statements

Income Statement

Three Months Ended June 30, — (In thousands, except share and per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenues, Net6,3182,8178,3005,223
Cost of Goods Sold344150512375
Gross Profit5,9742,6677,7884,848
Operating Expenses2,1833,0374,8206,198
Income (Loss) from Operations3,791-3702,968-1,350
Net Income (Loss)1,339-1,135-1,996-3,465
Comprehensive Income (Loss)1,6842,901-2,569769
Net Income (Loss) per Share0.02-0.02-0.03-0.05
Weighted Average Common Shares Outstanding70,188,26363,865,57170,188,26363,865,571

Balance Sheet

(In thousands) (in thousands)

As of – June 30, 2026As of – December 31, 2025
Current Assets:Cash and cash equivalents2,8082,127
Current Assets:Accounts receivable, Net7092,804
Current Assets:Inventories, net1,5891,555
Current Assets:Prepaid expenses and other current assets8971,260
Current Assets:Total Current Assets6,0037,746
Current Assets:Property and Equipment, Net86113
Current Assets:Right of use assets808766
Current Assets:Investment in convertible bond8,69112,604
Current Assets:Investment in equity security580
Current Assets:Other Assets203207
Current Assets:Total Assets16,37021,436
Current Liabilities:Accounts payable and accrued expenses23,46622,615
Current Liabilities:Operating lease liabilities, current portion390348
Current Liabilities:Conversion feature derivative, notes payable9
Current Liabilities:Notes payable, current portion9,24711,151
Current Liabilities:Convertible notes payable, net of discount17,33317,380
Current Liabilities:Other current liabilities15,67117,578
Current Liabilities:Total Current Liabilities66,11669,072
Current Liabilities:Other long-term liabilities16,43015,972
Current Liabilities:Total Liabilities82,54685,044
Current Liabilities:Stockholders’ Deficit-66,176-63,608
Current Liabilities:Total Liabilities & Stockholders’ Deficit16,37021,436
Full release

Forward-looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking... (truncated)r time, including doubt about the company’s ability to continue as a going concern and other factors disclosed in the company’s Annual Report on Form 10-K for the year ended

December 31, 2025 filed with the SEC on March 31, 2026 and Quarterly Report on Form 10-Q filed on August 14, 2026, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

Company Contact:

Emmaus Life Sciences, Inc.

Investor Relations

(310) 214-0065

IR@emmauslifesciences.com

(Financial Tables Follow)³

(In thousands, except share and per share amounts)⁴

(In thousands)⁵

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.